IRIS
MENNINI, FRANCESCO SAVERIO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 28.415
EU - Europa 4.534
AS - Asia 3.853
SA - Sud America 691
AF - Africa 72
Continente sconosciuto - Info sul continente non disponibili 10
OC - Oceania 7
Totale 37.582
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 28.288
SG - Singapore 1.887
IT - Italia 1.746
CN - Cina 650
BR - Brasile 562
RU - Federazione Russa 497
IE - Irlanda 463
DE - Germania 401
VN - Vietnam 335
HK - Hong Kong 309
UA - Ucraina 309
FR - Francia 257
GB - Regno Unito 213
FI - Finlandia 184
SE - Svezia 136
JP - Giappone 102
ID - Indonesia 97
KR - Corea 96
NL - Olanda 92
IN - India 85
CA - Canada 75
PL - Polonia 48
AR - Argentina 42
IQ - Iraq 37
BD - Bangladesh 36
ES - Italia 32
IR - Iran 31
BE - Belgio 30
ZA - Sudafrica 30
AT - Austria 29
CH - Svizzera 27
MX - Messico 26
EC - Ecuador 23
PH - Filippine 21
TW - Taiwan 21
TR - Turchia 20
CL - Cile 18
PK - Pakistan 17
CO - Colombia 16
SA - Arabia Saudita 15
AE - Emirati Arabi Uniti 14
MY - Malesia 13
JO - Giordania 10
EU - Europa 9
UZ - Uzbekistan 9
PT - Portogallo 8
RO - Romania 8
UY - Uruguay 8
EG - Egitto 7
IL - Israele 7
AU - Australia 6
CZ - Repubblica Ceca 6
JM - Giamaica 6
MA - Marocco 6
PY - Paraguay 6
VE - Venezuela 6
AL - Albania 5
BO - Bolivia 5
DK - Danimarca 5
DZ - Algeria 5
GR - Grecia 5
LT - Lituania 5
TH - Thailandia 5
BG - Bulgaria 4
BH - Bahrain 4
HR - Croazia 4
NP - Nepal 4
OM - Oman 4
AZ - Azerbaigian 3
DM - Dominica 3
GH - Ghana 3
HN - Honduras 3
HU - Ungheria 3
KE - Kenya 3
KG - Kirghizistan 3
KZ - Kazakistan 3
MN - Mongolia 3
NO - Norvegia 3
RS - Serbia 3
SV - El Salvador 3
AO - Angola 2
BY - Bielorussia 2
CI - Costa d'Avorio 2
DO - Repubblica Dominicana 2
ET - Etiopia 2
GY - Guiana 2
HT - Haiti 2
LB - Libano 2
MK - Macedonia 2
PE - Perù 2
SI - Slovenia 2
SK - Slovacchia (Repubblica Slovacca) 2
SN - Senegal 2
TN - Tunisia 2
TT - Trinidad e Tobago 2
ZM - Zambia 2
BA - Bosnia-Erzegovina 1
BB - Barbados 1
BN - Brunei Darussalam 1
CG - Congo 1
Totale 37.559
Salva come PNG Salva come JPEG
Città #
Wilmington 7.138
Houston 6.888
Woodbridge 6.755
Singapore 1.004
Fairfield 906
Ashburn 563
Chandler 498
San Jose 486
Ann Arbor 426
Dublin 386
Seattle 344
Rome 335
Hong Kong 305
Cambridge 296
Medford 293
Beijing 260
New York 259
Jacksonville 257
Council Bluffs 204
Milan 198
Dearborn 182
Santa Clara 166
The Dalles 156
Lawrence 136
Los Angeles 134
Helsinki 120
Lauterbourg 106
Dong Ket 94
Tokyo 93
Moscow 91
San Diego 86
Jakarta 77
Ho Chi Minh City 68
Buffalo 67
Hanoi 67
Dallas 63
Menlo Park 58
North Bergen 53
São Paulo 50
Phoenix 47
Nuremberg 39
London 37
Chicago 35
Orem 31
Toronto 30
Catania 29
Redwood City 28
Florence 27
Verona 27
Mülheim 25
Seoul 25
Warsaw 25
Amsterdam 24
Chennai 24
Turin 24
Brussels 23
Nanjing 23
Naples 22
Frankfurt am Main 20
Munich 20
Belo Horizonte 19
Da Nang 18
Norwalk 18
Redondo Beach 17
Bologna 16
Guangzhou 16
Johannesburg 16
Napoli 16
Parma 16
Rio de Janeiro 16
San Francisco 16
Boardman 15
Denver 15
Hangzhou 15
Paris 15
Miami 14
Shanghai 14
Taipei 14
Manchester 13
Zurich 13
Creede 12
Curitiba 12
Falls Church 12
Haiphong 12
Kraków 12
Madrid 12
Messina 12
Montreal 12
Ottawa 12
Perugia 12
Brasília 11
Falkenstein 11
Genoa 11
Monmouth Junction 11
Palermo 11
University Park 11
Bari 10
Lappeenranta 10
Mountain View 10
Poplar 10
Totale 30.791
Salva come PNG Salva come JPEG
Nome #
Strategie e performance nel mercato farmaceutico italiano: un'analisi empirica 564
Extending influenza vaccination to individuals aged 50-64: a budget impact analysis 534
A one-year prospective costing study of botulinum toxin type A treatment of chronic tension headache 475
A one-year retrospective economic evaluation of botulinum toxin type A treatment of chronic tension headache 471
General disease costing principles 463
Economic Burden of Human Papillomavirus-Related Diseases in Italy 462
Treatment plan comparison in acute and chronic respiratory tract diseases: an observational study of doxophylline vs. theophylline 456
Governance of preventive health intervention and on time verification of its efficiency: the GIOVE study 454
Economic effects of treatment of chronic kidney disease with low-protein diet 448
The perception of corruption in health: AutoCM methods for an international comparison 448
anti-TNF agents as therapeutic choice in immune-mediated inflammatory diseases: focus on adalimumab. 446
Scenari e strategie nel settore farmaceutico 440
Health Utilities Lost and Risk Factors Associated With HPV-induced Diseases in Men and Women: The HPV Italian Collaborative Study Group 439
Artificial neural networks and their potentialities in analyzing budget health data: an application for Italy of what-if theory 437
Cost of poor adherence to anti-hypertensive therapy in five European countries 436
Hospital costs incurred by the Italian national health service for invasive cervical cancer 427
Towards the eradication of HPV infection through universal specific vaccination 426
Cost-effectiveness analysis for the treatment of chronic kidney disease with low-protein diet 426
Rapid responses to: Letter to the Editor, by L. Garattini and G. Casadei [Vaccine 27 (38) (20 August 2009) 5171] 425
Health and economic impact associated with a quadrivalent HPV vaccine in Italy 420
A One-Year Economic Evaluation of Botulinum Toxin Type A Treatment of Chronic Tension-type Headaches: Part II 420
The new perspectives of italian national health service 416
The role of tumour necrosis factor in the pathogenesis of immune-mediated diseases 413
Rapporto CEIS-Sanità 2005: sette parole chiave del SSN 410
The headache under-response to treatment (HURT) questionnaire, an outcome measure to guide follow-up in primary care: development, psychometric evaluation and assessment of utility. 409
Improving care through health economics analyses: cost of illness and headache 406
Rapporto CEIS-Sanità 2003: bisogni, risorse e nuove strategie 406
Cost-Effectiveness Analysis of Universal Human Papillomavirus Vaccination Using a Dynamic Bayesian Methodology: The BEST II Study 402
Oral vs injection therapy in the treatment of metastatic colorectal cancer. a cost minimization analysis in a public hospital of the lazio region [Terapia orale vs terapia infusionale nel trattamento del cancro del colon retto localmente avanzato o avanzato analisi di minimizzazione dei costi presso una struttura ospedaliera della regione lazio] 399
Rapporto CEIS-Sanità 2007: responsabilità, autonomia, sussidiarietà, integrazione, valutazione, empowerment: 6 "nuove" parole chiave per il futuro del SSN 395
Rapporto CEIS-Sanità 2004: sostenibilità, equità e ricerca dell'efficienza 394
Public health value of universal HPV vaccination 394
Economic burden of schizophrenia in Italy: a probabilistic cost of illness analysis 393
Pilot evaluation of indirect costs and the impact of bipolar disorder type I 392
Anti-HPV vaccination in Italy: a review of recent economic data for Italy 391
Time to market and patient access to new oncology products in Italy: a multistep pathway from European context to regional healthcare providers 390
Healthcare resource utilization among patients with relapsed multiple myeloma in the UK, France, and Italy 389
The Welfare States in a United Europe 385
Criteri per l'allocazione regionale delle risorse per la sanità: riflessioni sul caso italiano 383
Population-based frequency assessment of HPV-induced lesions in patients with borderline Pap tests in the Emilia-Romagna Region: the PATER study 380
Economic evaluation of spondyloarthritis: Economic impact of diagnostic delay in Italy 378
Joint Procurement and the EU perspective. In Law and Economics of Public Procurement reforms 375
Equità e fairness del servizio sanitario nazionale italiano 370
Does regional belonging explain the similarities in the expenditure determinants of Italian healthcare deliveries?: An approach based on Artificial Neural Networks 369
Economic Burden of Rheumatoid Arthritis in Italy: Possible Consequences on Anti-Citrullinated Protein Antibody-Positive Patients 366
Economic burden of diverticular disease: An observational analysis based on real world data from an Italian region 360
Dinamiche e determinanti del settore farmaceutico in Europa 359
Primary Biliary Cholangitis: advances in management and treatment of the disease 356
Burden of Disease of Human Papillomavirus (HPV): Hospitalizations in the Marche and Veneto Regions. An observational study 354
Improving care through health economics analyses: cost of illness and headache (general disease costing principles) 353
Human papillomavirus 9-valent vaccine for cancer prevention: A systematic review of the available evidence 352
Direct and indirect costs associated with respiratory allergic diseases in Italy. A probabilistic cost of illness study. [Costi diretti e indiretti associati a malattie allergiche respiratorie in Italia. Uno studio probabilistico di cost of illness] 351
PDB51. Direct and indirect cost of diabetes in italy: A prevalence probabilistic approach 350
The economic burden of musculoskeletal disorders on the Italian social security pension system estimated by a Monte Carlo simulation 348
The economic value of vaccinations: a systematic review of Italian economic evaluations and HTA reports. 348
Hepatitis C virus prevalence and level of intervention required to achieve the WHO targets for elimination in the European Union by 2030: a modelling study 346
Time trade-off procedure for measuring health utilities loss with human papillomavirus–induced diseases: a multicenter, retrospective, observational pilot study in Italy 344
Il settore industriale sanitario in Italia 342
Cost per response for abatacept versus adalimumab in rheumatoid arthritis by ACPA subgroups in Germany, Italy, Spain, US and Canada 338
A novel method to value real options in health care: The case of a multicohort human papillomavirus vaccination strategy 326
Fraud and Corruption in Healthcare: Recognizing Such Phenomena to Combat Them. 321
Dimensioni e tendenze del mercato farmaceutico in Italia (1980/1997) 317
Analisi di impatto di budget di pasireotide in pazienti con Acromegalia nella prospettiva del Servizio Sanitario Nazionale 316
Health policy model: Long-term Predictive results associated with the management of hepatitis C virus-induced diseases in Italy 311
Strategie e performance delle grandi aziende farmaceutiche in Italia (1979-2001) 306
Il settore industriale farmaceutico italiano 306
Economic impact of biosimilar drugs in Italy: past, present and future of infliximab and etanerceptt 304
Impact of new DAA therapy on real clinical practice: A multicenter region-wide cohort study 297
Direct and Indirect Costs of Immunoglobulin Replacement Therapy in Patients with Common Variable Immunodeficiency (CVID) and X-Linked Agammaglobulinemia (XLA) in Italy 296
Early treatment in HIV patients: a cost–utility analysis from the Italian perspective 290
Economic burden of HPV9-related diseases: a real-world cost analysis from Italy 290
Introduzione 288
Economics of Headache 282
Economic Consequences of Investing in Anti-HCV Antiviral Treatment from the Italian NHS Perspective: A Real-World-Based Analysis of PITER Data 282
Cost-effectiveness analysis of the nine-valent HPV vaccine in Italy 271
null 263
Erratum to: Artificial neural networks and their potentialities in analyzing budget health data: an application for Italy of what-if theory 259
Invecchiamento della popolazione e sostenibilità del SSN:il ruolo della Health Technology Assessment (HTA) per la valutazione tecnica, economica ed organizzativa della Sanità del futuro 248
Screening strategies for Hepatitis C Virus elimination in Italy 245
The economic impact of biosimilars in Italy: a scenario analysis 245
Using real-world data to estimate the Social Security Costs of Retinal Diseases: Results from the Observatory on Legal Blindness 244
Cost Estimate of Immune-Related Adverse Reactions Associated with Innovative Treatments of Metastatic Melanoma 237
Budget Impact Analysis della gestione dell'agitazione psicomotoria con loxapina inalatoria in Italia. 236
HPV Vaccination Concepts in the Reality of Today 236
La corruzione in sanità: i nuovi strumenti per individuarla e contrastarla 234
Rationale and budget impact of bimonthly use of Cetuximab in patients with recurrent and/or metastatic head and neck cancer 232
Economic evaluation of the treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSIs) from the national payer perspective: introduction of a new treatment to the patient journey. A simulation of 3 European Countries 232
Probabilistic cost-effectiveness analysis of controlled ovarian stimulation with recombinant FSH plus recombinant LH vs. Human menopausal gonadotropin for women undergoing IVF 231
Cost-effectiveness of switching from trivalent to quadrivalent inactivated influenza vaccines for the at-risk population in Italy 207
Budget impact of bimonthly use of cetuximab in patients diagnosed with metastatic colorectal cancer 205
Analisi di Budget Impact su modelli di acquisto e gestione degli ausili per l’incontinenza urinaria a confronto 202
Budget Impact Analysis of Dalbavancin in the Treatment of Acute Bacterial Skin and Skin Structure Infections in Three European Countries 202
Economic Consequences of Anti-HCV Antiviral Treatment Investment from the NHS Perspective 195
Economic burden of disease of uncontrolled acromegalic patients: the acromegaly Italian collaborative study group 187
Artificial Urinary Sphincters as a Treatment for Post-Prostatectomy Severe Urinary Incontinence in Italy: A Cost-Utility Analysis 184
Estimation of the number of HCV-positive patients in Italy 173
PIN79 - ECONOMIC CONSEQUENCES OF ANTI-HCV ANTIVIRAL TREATMENT INVESTMENT FROM THE NHS PERSPECTIVE: A REAL-WORLD-BASED ANALYSIS FROM PITER DATA 172
The burden of atopic dermatitis in adults in Italy 171
Ipercolesterolemia e rischio cardiovascolare in Italia: modello di cost of illness. 163
Burden economico della neuropatia ottica ereditaria di Leber (LHON) in Italia: stima dei costi indiretti e diretti a carico del paziente. 163
Totale 33.992
Salva come PNG Salva come JPEG
Categoria #
all - tutte 94.226
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 94.226
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021562 0 0 0 0 0 0 0 0 0 145 235 182
2021/20221.594 77 129 139 88 71 87 148 143 94 82 147 389
2022/20231.701 176 111 51 198 148 403 163 104 142 33 118 54
2023/2024946 87 44 66 31 79 226 66 50 61 52 45 139
2024/20253.424 117 831 348 228 106 265 214 172 308 394 205 236
2025/20264.687 335 164 534 349 436 293 749 650 716 461 0 0
Totale 38.046